Advanced Nanomedicines for the Treatment and Diagnosis of Myocardial Infarction and Heart Failure

ISSN: 1873-5592 (Online)
ISSN: 1389-4501 (Print)


Volume 15, 14 Issues, 2014


Download PDF Flyer




Current Drug Targets

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 52nd of 254 in Pharmacology & Pharmacy

Submit Abstracts Online Submit Manuscripts Online

Editor-in-Chief:
Francis J. Castellino
Kleiderer-Pezold Professor of Biochemistry
Director, W.M. Keck Center for Transgene Research
Dean Emeritus, College of Science
230 Raclin-Carmichael Hall, University of Notre Dame
Notre Dame, IN 46556
USA


View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 3.597
5 - Year: 3.558

Advanced Nanomedicines for the Treatment and Diagnosis of Myocardial Infarction and Heart Failure

Author(s): Mónica P. A. Ferreira, Vimalkumar Balasubramanian, Jouni Hirvonen, Heikki Ruskoaho and Helder A. Santos

Affiliation: Division of Pharmaceutical Chemistry and Technology Faculty of Pharmacy, University of Helsinki FI-00014 Helsinki, Finland

Abstract

Nanotechnology has impacted tremendously the medical research with increasing importance in the development of new therapeutic approaches and applications. Among these applications, the use of nanocarriers have gained particular interest in order to achieve successful delivery of therapeutics and imaging agents for the treatment and diagnostics of different diseases, such cancer, infections, diabetes and lung, brain and cardiovascular diseases. Heart failure (HF) is a complex clinical syndrome derived from multiple causes that arise from secondary to inherited or acquired abnormalities of cardiac structure and/or function. Myocardial infarction (MI), the major cause of HF, continues to be an increasing problem in terms of morbidity, mortality and healthcare costs worldwide. Currently, established pharmacologic drugs have proven to be effective in reducing hypertrophy, remodeling of the myocardium, and reduce morbidity and mortality in patients with HF. However, despite optimal treatment with existing drugs, the prognosis of HF is poor, and also the possible deleterious effects of therapeutic agents must be considered when used at doses required for the desired therapeutic effect. Therefore, novel therapeutic strategies are urgently needed to prevent high morbidity and mortality associated with MI and HF. In this review, we will present recent developments in nanomedicine research envisaged to have an important impact on the treatment of cardiovascular diseases, particularly MI. In addition, we will discuss the use of different advanced modified nanosystems for molecular imaging and therapeutics of MI, presenting several in vitro and in vivo examples. Finally, we will conclude with an overview of the potential of nanomedicines in the future for the treatment of cardiovascular diseases


Purchase Online Rights and Permissions

  
  



Article Details

Volume: 15
First Page: 1
Page Count: 1
DOI: 10.2174/1389450115666140821115225
Advertisement

Related Journals




Webmaster Contact: urooj@benthamscience.org Copyright © 2014 Bentham Science